NCT03135951View on ClinicalTrials.gov

Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

February 19, 2018

Study Completion Date

May 18, 2018

Conditions
Breast CancerPharmacokinetics
Interventions
DRUG

SPI-2012

Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.

Trial Locations (1)

92804

Research Center, Anaheim

All Listed Sponsors
lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT03135951 - Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy | Biotech Hunter | Biotech Hunter